Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0584
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy ; volume:102 ; number:2 ; day:28 ; month:12 ; year:2022 ; pages:323-328 ; date:2.2023
Annals of hematology ; 102, Heft 2 (28.12.2022), 323-328, 2.2023

Urheber
Klement, Piroska
Fiedler, Walter
Gabdoulline, Razif
Dallmann, Louisa-Kristin
Wienecke, Clara Philine
Schiller, Johannes
Kandziora, Christian
Teich, Katrin
Heida, Bennett
Büttner, Konstantin
Brandes, Maximilian
Funke, Carolin
Wichmann, Martin
Othman, Basem
Chromik, Joerg
Amberg, Stefanie
Kebenko, Maxim
Schlipfenbacher, Vera
Wilke, Anne Christine
Modemann, Franziska
Janning, Melanie
Serve, Hubert
Bokemeyer, Carsten
Theile, Susann
Deppermann, Ute
Kranich, Anne L.
Ganser, Arnold
Thol, Felicitas
Heuser, Michael
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00277-022-05075-4
URN
urn:nbn:de:101:1-2023040621081741275825
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:52 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Klement, Piroska
  • Fiedler, Walter
  • Gabdoulline, Razif
  • Dallmann, Louisa-Kristin
  • Wienecke, Clara Philine
  • Schiller, Johannes
  • Kandziora, Christian
  • Teich, Katrin
  • Heida, Bennett
  • Büttner, Konstantin
  • Brandes, Maximilian
  • Funke, Carolin
  • Wichmann, Martin
  • Othman, Basem
  • Chromik, Joerg
  • Amberg, Stefanie
  • Kebenko, Maxim
  • Schlipfenbacher, Vera
  • Wilke, Anne Christine
  • Modemann, Franziska
  • Janning, Melanie
  • Serve, Hubert
  • Bokemeyer, Carsten
  • Theile, Susann
  • Deppermann, Ute
  • Kranich, Anne L.
  • Ganser, Arnold
  • Thol, Felicitas
  • Heuser, Michael
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial

Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial

Verbundene Objekte